Ravulizumab

Study of Ravulizumab in Pediatric Participants With Primary IgAN

ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Ravulizumab Outcomes in Polish Patients With aHUS

Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Real-life Treatment Outcomes of Ravulizumab in PNH

Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Real Life Use of Ravulizumab in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis